

Protalix BioTherapeutics, Inc.  
Form 8-K  
June 03, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 3, 2008**

**Protalix BioTherapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Florida**

(State or other jurisdiction of incorporation)

**000-27836**

(Commission File Number) **65-0643773**

(IRS Employer Identification No.)

**2 Snunit Street  
Science Park  
POB 455  
Carmiel, Israel 20100**

(Address of principal executive offices) (Zip Code)

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

Registrant's telephone number, including area code: **+972-4-988-9488**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-



**Item 8.01. Other Events**

On June 3, 2008, Protalix BioTherapeutics, Inc. (the Company ) issued a press release announcing that it intends to initiate a double blind, follow-on extension study as part of the Company s on-going phase III clinical trial of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD) for the treatment of Gaucher disease, a lysosomal storage disorder in humans. The press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1

Press release dated June 3, 2008.

2

---



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: June 3, 2008

By:

/s/ David Aviezer

Name:

David Aviezer, Ph.D.

Title:

President and Chief Executive Officer